Placenta Safe™ Complete Plus

Placenta Safe™ Complete Plus – is a non-invasive prenatal test (NIPT) that includes two tests - Placenta Safe™ Karyo Plus and Placenta Safe™ Gene Complete. The purpose of the test is to detect aneuploidies of all chromosomes and identify changes in the number of copies of genetic material fragments within certain chromosomes, i.e., large deletions and duplications (CNVs, copy number variants) larger than 7 Mb, and 9 syndromes associated with microdeletions: DiGeorge (22q11.2 del), Cri-du-chat (5p15.2 del), Angelman/Prader-Willi (15q11.2-q13.1 del), 1p36 deletions, Wolf-Hirschhorn (4p16.3 del), Jacobsen (11q23.3-q25 del), Langer-Giedion (8q24.11-q24.13 del), Smith-Magenis (17p11.2 del). It also screens for 44 autosomal dominant inherited monogenic diseases (genes ASXL1, BRAF, CBL, CHD7, COL1A1, COL1A2, COL2A1, FGFR2, FGFR3, HDAC8, JAG1, KRAS, MAP2K1, MAP2K2, MECP2, NIPBL, NSD1, NRAS, PTPN11, RAF1, RIT1, SHOC2, SOS1, SETBP1, SIX3), and 5 autosomal recessive inherited diseases: cystic fibrosis (gene CFTR), beta-thalassemia (HBB), sickle cell anemia (HBB), type 1A deafness (CX26 (GJB2) and type 1B deafness (gene CX30 (GJB6)). The test results determine the likelihood that the fetus may have the tested chromosomal and genetic anomalies.

In the case of dichorionic twins, microdeletions and sex chromosome aneuploidies are not detected.
For the test for recessive diseases, a DNA sample from the fetus's father is taken from the inner cheek or venous blood.

Recommendation for when to perform the test: Single and twin - from 10 weeks of pregnancy.

Sample: blood.

Execution time after reaching the laboratory: 1st report: 5-8 business days, 2nd report: 10-20 business days.